Associations between use of cocaine, amphetamines, or psychedelics and psychotic symptoms in a community sample

Acta Psychiatrica Scandinavica

Volumn 123, Issue 6, 2011, Pages 466-474

  Kuzenko, N ^a   Sareen, J ^a   Beesdo Baum, K ^b   Perkonigg, A ^b   Hofler M ^b   Simm, J ^a   Lieb, R ^c,d   Wittchen, H U ^b,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Amphetamine; Cocaine; Psychedelics; Psychoses; Substance related disorders

Indexed keywords

AMPHETAMINE; COCAINE; PSYCHEDELIC AGENT;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; COMMUNITY SAMPLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; GERMANY; HUMAN; LIFESPAN; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; MUNICH COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; AMPHETAMINES; COCAINE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HALLUCINOGENS; HUMANS; INTERVIEW, PSYCHOLOGICAL; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; ODDS RATIO; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RESIDENCE CHARACTERISTICS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79955973776     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01633.x     Document Type: Article

References (58)

1. Lieb R, Schuetz CG, Pfister H, Von Sydow K, Wittchen H-U. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 2002;68:195-207.
2. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States. Arch Gen Psychiatry 2007;64:566-576.
3. Wittchen H-U, Frölich C, Behrendt S et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007;88(Suppl 1):60-70.
4. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 1990;178:473-480.
5. Arsenault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-1213.
6. Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319-327.
7. Zammit S, Allebeck P, Aandreasson S et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002;325: doi:10.1136/bmj.325.7374.1199.
8. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005;100:354-366.
9. Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11; doi:10.1136/bmj.38267.664086.63.
10. Wiles NJ, Zammit S, Bebbington P, Singleton N, Meltzer H, Lewis G. Self-reported psychotic symptoms in the general population. Results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry 2006;188:519-526.
11. Mazzoncini R, Donoghue K, Hart J et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand 2009;121:351-358.
12. Mcgrath J, Welham J, Scott J et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; doi:10.1001/archgenpsychiatry.2010.6.
13. Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry 1999;14:366-371.
14. Ringen PA, Melle I, Birkenæs AB et al. Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr Scand 2008;117:133-138.
15. Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med 2001;31:659-668.
16. Farrell M, Boys A, Bebbington P et al. Psychosis and drug dependence: results from a national survey of prisoners. Br J Psychiatry 2002;181:393-398.
17. Mcketin R, Mclaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006;101:1473-1478.
18. Barnett JH, Werners U, Secher SM et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007;190:515-520.
19. Mc Lellan AT, Woody GE, O'brien CP. Development of psychiatric illness in drug abusers. Possible role of drug preference. NEJM 1979;301:1310-1314.
20. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996;40:1155-1163.
21. Cantor-Graae E, Nordstrom LG, Mcneil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001;48:69-82.
22. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 1988;45:1023-1031.
23. Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 1979;208:203-209.
24. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985;9:469-477.
25. Lang UE, Puls I, Müller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007;20:687-702.
26. Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131-181.
27. Stahl SM. Stahl's Essential Psychopharmacology, 3rd edn. New York: Cambridge University Press, 2008.
28. Van Os J, Jones P, Sham P, Bebbington P, Murray RM. Risk factors for onset and persistence of psychosis. Soc Psychiatry Psychiatr Epidemiol 1998;33:596-605.
29. Van Os J, Hanssen M, Bijl R, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001;58:663-668.
30. Wittchen H-U, Perkonigg A, Lachner G, Nelson CB. Early Developmental Stages of Psychopathology Study (EDSP): objectives and design. Eur Addict Res 1998;4:18-27.
31. Lieb R, Isensee B, Von Sydow K, Wittchen H-U. The early developmental stages of psychopathology study (EDSP): a methodological update. Eur Addict Res 2000;6:170-182.
32. Wittchen H-U, Pfister H. DIA-X Interviews: Manual Für Screeningverfahren und Interview: PC Programm zur Durchführung des Interviews (Längs-und Querschnittuntersuchung); Auswertungsprogramm. Frankfurt: 1997, Swets & Zeitlinger.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
34. Reed V, Gander F, Pfister H et al. To what degree the Composite International Diagnostic Interview (CIDI) correctly identifies DSM-IV disorders? Int J Methods Psychiatr Res 1998;7:142-155.
35. Wittchen H-U, Lachner G, Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998;33:568-578.
36. Lachner G, Wittchen H-U, Perkonigg A et al. Structure, content and reliability of Munich-Composite International Diagnostic Interview (M-CIDI) substance use sections. Eur Addict Res 1998;4:28-41.
37. Lieb R, Pfister H, Wittchen H-U. Use, abuse and dependence of prescription drugs in adolescents and young adults. Eur Addict Res 1998;4:67-74.
38. Lieb R, Schreier A, Pfister H, Wittchen H-U. Maternal smoking and smoking in adolescents: a prospective community study of adolescents and their mothers. Eur Addict Res 2003;9:120-130.
39. Perkonigg A, Pfister H, Höfler M et al. Substance use and substance use disorders in a community sample of adolescents and young adults: incidence, age effects and patterns of use. Eur Addict Res 2006;12:187-196.
40. Behrendt S, Wittchen H-U, Höfler M et al. Risk and speed of transitions to first alcohol dependence symptoms in adolescents: a 10-year longitudinal community study in Germany. Addiction 2008;103:1638-1647.
41. Perkonigg A, Goodwin RD, Fiedler A et al. The natural course of cannabis use, abuse, and dependence during the first decades of life. Addiction 2008;103:439-449.
42. Wittchen H-U, Behrendt S, Höfler M et al. What are the high risk periods for incident substance use and transitions to abuse and dependence? Implications for early interventions and prevention Int J Methods Psychiatr Res 2008;17(Suppl 1):16-29.
43. Behrendt S, Wittchen H-U, Höfler M, Lieb R, Beesdo K. Transitions from first substance use to substance use disorders in adolescence: is early onset associated with a rapid escalation? Drug Alcohol Depend 2009;99:68-78.
44. Wittchen H-U, Behrendt S, Höfler M et al. A typology of cannabis-related problems among individuals with repeated illegal drug use in the first three decades of life: evidence for heterogeneity and different treatment needs. Drug Alcohol Depend 2009;102:151-157.
45. STATACORP. STATA Statistical Software. Release 10.1 ed. Texas: College Station, 2009.
46. Koreen AR, Siris SG, Chakos M, Alvir J, Maverhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry 1993;150:1643-1648.
47. Michail M, Birchwood M. Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia. Br J Psychiatry 2009;195:234-241.
48. Kastelan A, Franciskovic T, Moro L et al. Psychotic symptoms in combat-related post-traumatic stress disorder. Mil Med 2007;172:273-277.
49. Brewin CR, Patel T. Auditory pseudohallucinations in United Kingdom war veterans and civilians with posttraumatic stress disorder. J Clin Psychiatry 2010;71:419-425.
50. Harford TC, Grant BF, Yi HY, Chen CM. Patterns of DSM-IV alcohol abuse and dependence criteria among adolescents and adults: results from the 2001 National Household Survey on Drug Abuse. Alcohol Clin Exp Res 2005;29:810-828.
51. Burgess C, O'donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry 2000;15:287-294.
52. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007;115:304-309.
53. Regier DA, Farmaer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
54. Curran C, Byrappa N, Mcbride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004;185:196-204.
55. Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 1984;172:577-595.
56. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the cathecol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-1127.
57. Matsuzawa D, Hashimoto K, Miyatake R et al. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry 2007;164:1105-1114.
58. White T, Schmidt M, Karatekin C. White matter 'potholes' in early-onset schizophrenia: a new approach to evaluate white matter microstructure using diffusion tensor imaging. Psychiatry Res 2009;174:110-115.